MDS
Advertisement
Daily oral administration of the agent brought favorable transfusion independence performance and overall safety.
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Luspatercept led to decreases RBCT burden vs epoetin alfa in patients with LR-MDS.
A transcriptomic analysis saw CDK8 repression increase expression of myeloid differentiation and oncogenesis genes in HSPCs.
In a study, lack of response to the doublet was most prevalent in multi-hit TP53 as compared with wild type or single-hit.
The investigators compiled patients' quality of life, social function, and physical scores, and assessed overall survival.
The US FDA conferred with experts on ways to improve CMML clinical trials and accelerate treatment advances in this disease.
Phase II trial results suggest limits to the IL-1β inhibitor's efficacy by patient genetic complexity and SF3B1 mutation.
Rapamycin can normalize erythroid differentiation in SF3B1-mutated MDS by acting upon the mTOR signaling pathway.
US FDA researchers analyzed randomized, controlled, multicenter MDS trials for connections between OS, EFS, CR, and PR.
The combination was well-tolerated and the recommended dose determined for the phase II component of an ongoing trial.
Cohort patients had at least one prior intervention with luspatercept, lenalidomide, an HMA or ESA, or were ESA-ineligible.
The favorable effects from pharmacologic iron restriction may also be enhanced when used with an erythroid maturation agent.
Analysts advise that CMML that features AML-associated mutations should undergo management approaches typically used for AML.
Expert panel consensus produced a set of genomics-based disease categories from the two systems' morphology-based categories.
Clinicians seek alternatives to biopsy for clinically evaluating bone marrow mutations in cytopenic patients.
A retrospective study's insights help inform timing decisions regarding allogenic HCT in patients with MDS or CMML.
Investigators examined patients' baseline transfusion burdens and erythropoietin levels for correlations with agent response.
The COMMANDS trial data underscore luspatercept as the preferred treatment for disease not previously exposed to ESAs.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.